Summit Therapeutics Inc. filed a Form 8-K on November 4, 2026, disclosing a stockholder-approved amendment to its Restated Certificate of Incorporation that doubles authorized common stock from 1,000,000,000 to 2,000,000,000 shares, alongside the release of its third-quarter 2026 financial results.

Key Highlights

  • Authorized shares doubled: Stockholders approved an increase of 1,000,000,000 authorized common shares, raising the total from 1,000,000,000 to 2,000,000,000.
  • Amendment effective November 4, 2026: Amendment No. 3 to the Restated Certificate of Incorporation was filed with the Delaware Secretary of State and became effective upon filing.
  • Vote breakdown: 658,142,561 shares voted for the proposal; 1,983,511 voted against; 3,134,826 abstained; and there were no broker non-votes.
  • Record date: Stockholders of record as of the close of business on October 1, 2026 were eligible to vote at the Special Meeting.
  • Q3 2026 results released: The company also issued a press release on November 4, 2026, announcing financial results and operational progress for the third quarter ended September 30, 2026.

Summit Therapeutics Special Meeting: Share Authorization Vote and Q3 Disclosure

According to the filing, Summit Therapeutics Inc. (NASDAQ:SMMT) held a Special Meeting of Stockholders on November 4, 2026, at which stockholders voted on a single proposal: Amendment No. 3 to the company's Restated Certificate of Incorporation. The amendment increases the number of authorized shares of common stock by 1,000,000,000, bringing the total authorized common shares from 1,000,000,000 to 2,000,000,000. The company disclosed that the proposal was approved "in accordance with the recommendation of the Company's Board of Directors."

The filing reports that 658,142,561 votes were cast in favor of the amendment, while 1,983,511 votes were cast against and 3,134,826 abstentions were recorded. No broker non-votes were reported. Following the stockholder vote, the company filed Amendment No. 3 with the Secretary of State of the State of Delaware on November 4, 2026, and the amendment became effective upon that filing, according to the disclosure.

Separately, the filing notes that on November 4, 2026, Summit Therapeutics issued a press release covering its financial results and operational progress for the third quarter ended September 30, 2026. That press release is furnished as Exhibit 99.1 to the Form 8-K. The filing specifies that the information provided under Item 2.02 and in Exhibit 99.1 "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934." The Form 8-K was signed by Manmeet S. Soni, identified as Chief Operating Officer, Chief Financial Officer and Director.

What Was Disclosed

Summit Therapeutics filed an 8-K on November 4, 2026, reporting stockholder approval of a 1,000,000,000-share increase in authorized common stock, the effective filing of Amendment No. 3 in Delaware, the vote tallies from the Special Meeting, and the furnishing of Q3 2026 financial results.